With time after solid-organ transplantation, cancer incidence and mortality increases and becomes the primary cause of death. Certain populations have an elevated chance of acquiring cancer after transplantation. To avoid cancer, lifestyle adjustment must be aggressively urged, and screening techniques should adhere to standardized norms, but may also need to be adapted to transplant-specific risk factors. The majority of screenings for solid organ cancer are identical to those conducted in the general population. For the purpose of posttansplant lymphoproliferative disorder (PTLD) monitoring, it is recommended that routine EBV testing using nucleic acid amplification methods be performed on individuals who are at high risk (donor EBV seropositive/recipient EBV seronegative). Following after the transplant operation, once during the first week after the procedure, once every month during the first three to six months, and once every three months until the end of the first post-transplant year. The use of ultrasound for routine screening of transplant recipients for renal cell carcinoma is not suggested, with the exception of high-risk people who are on kidney transplant waiting lists. Attenuation/modification of immunosuppression must balance patient-specific risk-versus-benefit classification. Population-based health data might potentially give answers and updates to unanswered issues.